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ized to one of the exercise programs or to the control condition, and differential effects on outcomes should be
attributed to this factor. The children’s fatness was reduced because of the exercise programs offered to those
groups. Mediation analysis (ie, testing factors posited to be
in the causal pathway) can suggest how those changes may
have occurred based on contemporaneous, collinear data with
varying precision. Mediation analyses on these data are in
progress.
As expected, puberty (ie, thelarche or gonadarche stage)
was a predictor in the insulin resistance models (insulin area
under the curve, P ⬍ .001; fasting insulin, P ⬍ .001; Matsuda index, P=.002). The adrenarche variable was not significant in any model. At the request of Short, we conducted an analysis of the interaction of thelarche or
gonadarche stage (classified as Tanner I, II, or III and above)
with the group⫻ time interaction in the insulin resistance
models, adjusting for cohort, sex, and race. An interaction
was detected only for fasting insulin, such that differential
change from baseline to posttest between exercise groups
and control was detected only in Tanner stage III or above.
In more developed children, similar decreases in fasting insulin were seen in the low-dose (adjusted mean difference,
⫺18.2 [95% CI, ⫺25.8 to ⫺10.6] U/mL) and high-dose
(⫺15.8 [95% CI, ⫺23.0 to ⫺8.5] U/mL) exercise groups
(each P ⬍ .001 vs the control group). Thus, more developed children might be more responsive to exercise. However, of 3 insulin resistance indicators, only 1 showed evidence of pubertal moderation. These exploratory analyses
provide scant support for the hypothesis that pubertal stage
affects the benefits of aerobic training in obese children. Conclusions should be tempered by the exploratory nature of
these additional analyses.
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Bisphenol A and Obesity in Children
and Adolescents
To the Editor: Dr Trasande and colleagues1 concluded that
“Urinary [bisphenol A] BPA concentration was significantly associated with obesity in this cross-sectional study
134

JAMA, January 9, 2013—Vol 309, No. 2

of children and adolescents. Explanations of the association cannot rule out the possibility that obese children ingest food with higher BPA content or have greater adipose
stores of BPA.”
The authors also examined other environmental phenols and did not find an association with obesity, stating
that “The absence of an association between body mass/
obesity and levels of other environmental phenols argues
for a specificity of association.”
The problem is that BPA is a lipophilic compound and
would have a propensity to be stored in fat, leading to an
increased amount in the urine of obese children. Bisphenol
A has a water solubility of 120 to 300 mg/L (practically insoluble in water).2,3 On the other hand, phenols as a group
have a great range in solubility. For example, phenol is soluble
in water at 83 g/L.3 The authors do not discuss the solubility of the other phenol compounds, which would have to
be comparably lipophilic to draw the conclusion that the
association is specific. In addition, the study was limited by
only measuring urine concentrations of BPA, which may not
reflect the serum level.
It was appropriate for Trasande et al1 to suggest that obese
people may have higher stores of BPA in their fat. If this is
indeed the case, then obesity would result in higher levels
of BPA in the urine and would not be the cause of obesity
but rather the result.
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In Reply: In our analysis of data from the 2003-2008 National Health and Nutrition Examination Survey (NHANES),
we found associations of urinary BPA (but not other chemically similar environmental phenols) with body mass index z score and obesity in children and adolescents, whether
the urinary concentration was categorized in quartiles or analyzed as a continuous variable. Dr Brent asserts that we failed
to account for the lipophilic nature of BPA and therefore
its propensity to be stored in the adipose tissue of obese individuals (especially compared with other environmental
phenols), invalidating our use of their urinary concentrations as tests of specificity.
©2013 American Medical Association. All rights reserved.
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To reinforce his assertion, Brent suggests that BPA has
low water solubility. However, one of his citations actually
states that BPA is “moderately soluble” in water.1 More recent reviews by the World Health Organization estimate BPA
solubility in water to be 0.5 to 1.3 mmol/L.2 Furthermore,
it is important to reflect on the metabolic transformation
of BPA in humans. After dietary ingestion, BPA undergoes
first-pass glycosylation in the liver, a process that increases
its urinary excretion as water-soluble glucuronide conjugates.3 The NHANES analytic method used to measure BPA
quantifies total (conjugated and unconjugated) BPA.4
The lipophilicity of BPA compared with the other environmental phenols can be evaluated by comparing the chemicals’ octanol and water partition coefficients—the higher the
coefficient, the more lipophilic the compound. Compared
with benzophenone-3, triclosan, and 4-tertoctylphenol, BPA
has a much lower partition coefficient (Kow, 2.2-3.4),2 and
therefore is less likely to be stored in fat than the other phenols. Thus, it was appropriate to examine associations of
urinary BPA alongside urinary concentrations of other environmental phenols, as we did in our study.
Brent’s comment presents an opportunity to reinforce that
our specificity tests have limits intrinsic to the crosssectional design. Absent controlled human experiments that
intentionally provide BPA doses to individuals and examine weight gain, observational, longitudinal studies are
needed to examine whether BPA may be associated with obesity or whether obese children simply excrete more BPA. If
further research reveals that the latter is more likely, our
study raises concerns that obese children may be susceptible to adverse neurodevelopmental and respiratory effects that have been associated with BPA exposure in children.5,6
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Strategies for Tailoring Asthma Treatment in Adults
To the Editor: The Best Adjustment Strategy for Asthma in
the Long Term (BASALT) trial conducted by Dr Calhoun
and colleagues1 compared 3 strategies for tailoring asthma
treatment in adult patients, including adjustment of inhaled steroids based on physician assessment, exhaled nitric oxide, and day-to-day symptoms. The data showed that
the exhaled nitric oxide or daily symptom strategies were
not superior to physician assessment with regard to treatment failure.
The BASALT trial is an example of an asthma treatment
algorithm study.2 These kind of studies aim to improve clinical outcome by tailoring treatment with existing drugs based
on predefined levels of a quantitative disease marker. The
design of such trials is pivotal, including choices regarding
the patient population, definition of the clinical end point,
clinical room for improvement, selection of the disease
marker, discrete levels of the marker leading to treatment
changes, and dose adjustments of the drug.3
The BASALT trial investigators made several choices that
may have affected the results. Exhaled nitric oxide is now
not the biomarker of choice—sputum eosinophils are.4 However, this is based on data from a recent meta-analysis and
the trial was designed more than 5 years ago. Also, the
BASALT trial investigators chose to enroll patients with mild
asthma who were well controlled with low-dose inhaled corticosteroids at baseline.1 This selection of well-controlled
patients may have limited the external validity of the study
and its generalizability to less well-controlled patients.
Control of these patients at baseline must have been determined by a physician assessment strategy, which is the
standard clinical procedure. Hence, the patients represent
a subgroup of patients with asthma and apparently good adherence who were probably doing well on physicianguided care prior to study inclusion. Is it surprising that the
same patients also did well by physician-guided care during the trial?
The present study does not answer the question of whether
the biomarker or daily symptom strategies are superior to
physician assessment in patients with uncontrolled asthma
at baseline. The latter group of patients showed the largest
benefit by biomarker-guided treatment in a previous study.5
Adding novel management strategies in patients for whom
the physician already knows best is not necessary. Such strategies may be needed for patients when the physician’s assessment fails.
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